Literature DB >> 8733794

Four behavioural syndromes of schizophrenia.

C R Harvey1, D A Curson, C Pantelis, J Taylor, T R Barnes.   

Abstract

BACKGROUND: A complementary approach to defining symptomatic subtypes of schizophrenia is to identify characteristic patterns of 'problem behaviours' associated with the capacity of patients to function in the community.
METHOD: In a large epidemiological survey, patients fulfilling Feighner criteria for schizophrenia were identified by key informants and assessed using the MRC Social Behaviour Schedule (SBS) and the Manchester Scale. An exploratory factor analysis was used to extract behavioural syndromes from the SBS data in order to compare the syndrome profiles in community, acute and long-stay subgroups and to examine their associations with symptoms and social functioning.
RESULTS: Four behavioural syndromes were identified: 'Thought disturbance', 'Social withdrawal', 'Depressed behaviour' and 'Anti-social behaviour', which distinguished between the patient subgroups and had significant differential relationships to symptoms and social functioning variables.
CONCLUSIONS: The evaluation of disability in schizophrenia and effectiveness of treatment interventions is incomplete without an assessment of problem behaviours.

Entities:  

Mesh:

Year:  1996        PMID: 8733794     DOI: 10.1192/bjp.168.5.562

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  7 in total

Review 1.  Instruments measuring behavioral disturbance in relatives with schizophrenia.

Authors:  H L Provencher; J P Fournier; M Perreault; J Vezina
Journal:  Community Ment Health J       Date:  2000-06

2.  Exploring the apparent absence of psychosis amongst the Borana pastoralist community of Southern Ethiopia. A mixed method follow-up study.

Authors:  Teshome Shibre; Solomon Teferra; Craig Morgan; Atalay Alem
Journal:  World Psychiatry       Date:  2010-06       Impact factor: 49.548

3.  Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop.

Authors:  Alan S Bellack; Michael F Green; Judith A Cook; Wayne Fenton; Philip D Harvey; Robert K Heaton; Thomas Laughren; Andrew C Leon; Donna J Mayo; Donald L Patrick; Thomas L Patterson; Andrew Rose; Ellen Stover; Til Wykes
Journal:  Schizophr Bull       Date:  2006-08-24       Impact factor: 9.306

4.  Pharmacological rescue in patient iPSC and mouse models with a rare DISC1 mutation.

Authors:  Nam-Shik Kim; Zhexing Wen; Jing Liu; Ying Zhou; Ziyuan Guo; Chongchong Xu; Yu-Ting Lin; Ki-Jun Yoon; Junhyun Park; Michelle Cho; Minji Kim; Xinyuan Wang; Huimei Yu; Srilatha Sakamuru; Kimberly M Christian; Kuei-Sen Hsu; Menghang Xia; Weidong Li; Christopher A Ross; Russell L Margolis; Xin-Yun Lu; Hongjun Song; Guo-Li Ming
Journal:  Nat Commun       Date:  2021-03-03       Impact factor: 14.919

5.  Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice.

Authors:  Weidong Li; Yu Zhou; J David Jentsch; Robert A M Brown; Xiaoli Tian; Dan Ehninger; William Hennah; Leena Peltonen; Jouko Lönnqvist; Matti O Huttunen; Jaakko Kaprio; Joshua T Trachtenberg; Alcino J Silva; Tyrone D Cannon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-02       Impact factor: 11.205

6.  A Preliminary Study of Rehabilitation Needs of In-patients and Out-patients with Schizophrenia.

Authors:  Sachin Gandotra; Sarita E Paul; Mercian Daniel; Krishan Kumar; Harsh A Raj; B Sujeetha
Journal:  Indian J Psychiatry       Date:  2004-07       Impact factor: 1.759

7.  Community outreach for patients who have difficulties in maintaining contact with mental health services: longitudinal retrospective study of the Japanese outreach model project.

Authors:  Mami Kayama; Yoshifumi Kido; Nozomi Setoya; Aki Tsunoda; Asami Matsunaga; Takahiro Kikkawa; Takashi Fukuda; Masayuki Noguchi; Keiko Mishina; Masaaki Nishio; Junichiro Ito
Journal:  BMC Psychiatry       Date:  2014-11-18       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.